中医药治疗脓毒症:从证据到创新药物发现
脓毒症全球疾病负担巨大,中医药在中国有超过两千年的临床实践,作为辅助治疗受到关注。本文评估了中医药在脓毒症管理中的应用,指出现有临床证据的潜在获益与方法学局限。血必净注射液是罕见在大规模、多中心、随机、双盲、安慰剂对照试验中显示疗效的制剂;而参附、参麦注射液等证据主要来自小型单中心研究,方法学局限显著。需要更多高质量多中心随机对照试验严格评估这些可能有益但当前验证不足的中药制剂。部分中药来源生物活性化合物的药理作用和机制已阐明,提示中药抗脓毒症药物发现的潜力。
要点
- 血必净注射液在大规模、多中心、随机、双盲、安慰剂对照试验中显示疗效,是现有中药制剂中证据最强的。
- 参附、参麦注射液等制剂的证据主要来自小型单中心研究,存在显著方法学局限。
- 绝大多数中药制剂用于脓毒症治疗缺乏稳健的临床证据。
- 需要更多高质量多中心随机对照试验严格评估可能有益但验证不足的中药制剂。
- 部分中药来源生物活性化合物的药理作用和机制已阐明,提示中药抗脓毒症药物发现潜力。
适用人群与场景
- 脓毒症患者,作为辅助治疗评估中医药应用
研究设计与关键结果
- 本文评估了中医药在脓毒症管理中的应用,指出绝大多数中药制剂缺乏稳健临床证据。
- 血必净注射液在大规模、多中心、随机、双盲、安慰剂对照试验中显示疗效。
- 参附、参麦注射液的证据主要来自小型单中心研究,方法学局限显著。
- 部分中药来源生物活性化合物的药理作用和机制已阐明。
证据类型、等级与局限
- 证据类型:综述。
- 血必净注射液证据来自大规模、多中心、随机、双盲、安慰剂对照试验。
- 参附、参麦注射液证据主要来自小型单中心研究,方法学局限显著。
- 绝大多数中药制剂缺乏稳健临床证据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为需要更多高质量、多中心随机对照试验来严格评估可能有益但当前验证不足的中药制剂。
- 作者强调继续研究以更好地将中医药与现代脓毒症管理整合,为开发循证中医药治疗铺路。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The global health burden of sepsis is immense, characterized by significant loss of life and high healthcare costs. Traditional Chinese medicine (TCM), with its over two millennia of clinical practice in China, has gained attention as a potential adjunctive approach for sepsis. Here, we evaluated TCM applications in sepsis management, highlighting both potential benefits and methodological limitations of existing clinical evidence. Although various TCM preparations have been evaluated for sepsis treatment, the vast majority lack robust clinical evidence. Xuebijing Injection represents a rare example that has demonstrated efficacy in a large-scale, multicenter, randomized, double-blind, placebo-controlled trial. In contrast, the evidence supporting other preparations such as Shenfu and Shenmai Injections comes primarily from smaller, single-center studies with significant methodological limitations. There is a clear need for more high-quality, multicenter randomized controlled trials to rigorously evaluate these potentially beneficial but currently insufficiently validated TCM preparations. The pharmacological effects and underlying mechanisms of some bioactive compounds derived from TCM medications have been elucidated, shedding light on the potential of TCM-based anti-sepsis drug discovery. We underscore the importance of continued research to better integrate TCM with modern sepsis management, paving the way for the development of evidence-based TCM treatments for this challenging condition.
参考来源
- Ji Y, Song H, Li L, et al. Traditional Chinese medicine for sepsis: advancing from evidence to innovative drug discovery. Crit Care. 2025. PMID: 40375087. doi:10.1186/s13054-025-05441-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。